Before the Diagnosis

She is sixty-eight, a retired teacher, and she has started closing browser tabs before the search results load.

It happens at 2 AM mostly. She types “early signs of Alzheimer’s” into Google, then stops. Closes the laptop. Goes back to bed. She tells herself she is being dramatic. Everyone forgets things. Everyone loses the thread of a conversation sometimes. Everyone reads a paragraph and has to start over.

But she knows. Something is different. She cannot name it, cannot prove it, but she knows the quality of this forgetting is not the same as misplacing her keys. It is the way her mind reaches for a word and finds only fog. The way she loses track of conversations not because she was distracted but because the information simply did not stick. The way her husband finishes her sentences now, not out of impatience but out of habit, because he has noticed too.

She has not told anyone. Not her doctor. Not her children. Not even her husband, not directly. She is waiting, she tells herself, for more evidence. What she is actually doing is hoping it will stop.

This is the space before diagnosis. It can last months or years. It is one of the loneliest places a person can be.

The Space Between Normal and Not

Cognitive changes with age are universal. Processing speed slows starting in the thirties. Working memory narrows. Word retrieval becomes less automatic. These are not signs of disease. They are signs of being human for several decades.

The question that haunts people is where normal aging ends and something else begins.

Researchers call this middle ground subjective cognitive decline, or SCD. The term describes people who notice changes in their own thinking but perform normally on standard cognitive tests. It is not a diagnosis. It is a risk state. Approximately one in four adults over sixty report subjective cognitive concerns. Most of them will never develop dementia. Some will.

What distinguishes concerning changes from ordinary aging is difficult to articulate but often clear to the person experiencing it. The forgetting feels different. The mental effort required for previously automatic tasks feels heavier. There is a quality of struggle that was not there before.

The terror of the question itself keeps many people silent for years. Asking means the answer might be yes. And so they Google at 2 AM and close the browser. They compensate, strategize, and cover. They wait until covering becomes impossible.

What Science Can Now See

For decades, the only way to confirm Alzheimer’s pathology in a living person was through a spinal tap or a PET scan. Both are expensive, invasive, and inaccessible for most people. A spinal tap means a needle in the lower back and a day of recovery. A PET scan means an injection of radioactive tracer, an hour in a scanner, and a bill that can exceed five thousand dollars.

This changed in May 2025, when the FDA cleared the first blood test for Alzheimer’s pathology. The Lumipulse G test measures two proteins: phosphorylated tau-217 and amyloid beta 1-42. The ratio between them can identify amyloid buildup in the brain with roughly 92 percent accuracy when compared to PET imaging.

The test is approved for symptomatic adults fifty-five and older. It requires a blood draw, a specialized laboratory, and a clinician who knows how to interpret the results. It is not yet recommended for screening people without symptoms, and it is not a diagnosis on its own. A positive result indicates amyloid pathology; it does not tell you whether that pathology will progress, how quickly, or what to do about it.

Still, the implications are significant. For the first time, a primary care physician can order a blood test that provides meaningful information about Alzheimer’s risk. This changes the diagnostic pathway. Instead of referring everyone with cognitive concerns to a specialist for expensive imaging, clinicians can use blood testing as a first step and reserve PET scans for confirmation when needed.

In February 2026, researchers published a model that uses p-tau217 levels to estimate when symptoms might begin. The so-called “clock” has a median accuracy of three to four years. It remains a research tool, not a clinical one, but it points toward a future where early detection becomes increasingly precise.

The Tools That Are Coming

Beyond blood tests, researchers are developing AI-powered screening tools that detect cognitive changes through speech, movement, and vision.

Speech analysis may be the closest to clinical use. Changes in word-finding, sentence complexity, pauses, and conversational flow appear years before a clinical diagnosis. Several companies are developing tools that analyze voice recordings for these patterns. The technology works; the question is how to deploy it responsibly in clinical settings.

Gait analysis looks at how people walk. Subtle changes in stride length, walking speed, and the ability to walk while performing a cognitive task (counting backward, for instance) correlate with cognitive decline. Sensor-based monitoring in homes or clinics could flag changes early. This remains largely in research settings.

Retinal imaging treats the eye as a window to the brain. The retina shares developmental origins with brain tissue, and AI analysis of retinal photographs can identify amyloid signatures and vascular changes associated with dementia. Early research is promising, but clinical deployment is years away.

Digital cognitive assessments, delivered through apps or websites, allow longitudinal tracking of cognitive performance over time. They are more sensitive to individual change than one-time tests because they establish a personal baseline. They are not a substitute for professional evaluation, but they add a data stream that did not exist a decade ago.

The honest assessment: these tools are promising, some are closer than others, and none of them replaces a thorough clinical evaluation by a trained professional. They may change how and when people enter the diagnostic pipeline. They will not eliminate the need for human judgment.

The Paradox of Knowing Early

Here is the question no one wants to ask: What happens when you can detect a disease you cannot yet cure?

For someone with symptoms, early detection now has clinical meaning. The FDA-approved treatments lecanemab and donanemab work only in early-stage Alzheimer’s with confirmed amyloid pathology. Detecting that pathology early opens a treatment window that did not exist three years ago. This is real progress.

For someone without symptoms, the calculus is more complicated. A positive blood test in an asymptomatic person predicts increased risk but cannot tell you whether you will develop dementia, when, or how severely. There is no approved treatment for preclinical Alzheimer’s outside of clinical trials. Knowing early allows for legal and financial planning, for conversations with family, for decisions about how to spend the years ahead. It also carries psychological weight that some people are not prepared to bear.

Surveys suggest that 79 percent of Americans say they would want to know if they were at elevated risk. What people say they want and what they experience when they receive the information are not always the same thing.

Two large trials are testing whether treatment before symptoms emerge can delay or prevent cognitive decline. The AHEAD study is evaluating lecanemab in people with amyloid buildup but no symptoms. TRAILBLAZER-ALZ 3 is doing the same with donanemab. Results are years away. Until they arrive, the benefit of detecting preclinical Alzheimer’s remains uncertain.

There is also the question of access. Blood tests require laboratory infrastructure, clinician education, and follow-up resources that are unevenly distributed. The communities at highest risk for Alzheimer’s, including Black and Hispanic Americans, are often the least likely to have access to these tools. Early detection that only reaches the privileged is not a public health solution.

What to Do If You Are Worried

If you are noticing changes in your thinking, the first step is the hardest: say it out loud.

Talk to your primary care physician. Be specific. “I’m forgetful” is too vague to act on. “I lose track of conversations even when I’m paying attention” or “I read a paragraph and cannot remember the beginning by the end” gives your doctor something concrete to evaluate.

Ask for a cognitive screening that goes beyond the Mini-Mental State Exam. The Montreal Cognitive Assessment (MoCA) is more sensitive to early changes. If your physician dismisses your concerns, find one who does not. You know your own mind better than anyone.

Ask about blood biomarker testing if you want more information. Understand what a positive or negative result would mean for you, and what you would do with that knowledge. Not everyone wants to know, and that is a legitimate choice.

Know the difference between changes that warrant investigation and changes that are simply part of aging. Slower word retrieval is common. Forgetting entire conversations is not. Needing more time to learn new things is normal. Getting lost in familiar places is not.

Consider who you need to tell and when. The isolation of carrying this alone makes everything harder. The people who love you will likely be less surprised than you expect. Many of them have noticed. They have been waiting for you to be ready to talk.

This series will cover what comes next: the epidemiology of Alzheimer’s, the other dementias that are often overlooked, what the new drugs actually do, what happens to the people providing care, who gets left out, and what remains when memory changes. The path ahead is difficult. Honest information is the best companion for walking it.

You are not alone in the space before diagnosis. Millions of people are there with you, Googling at 2 AM, closing the browser, lying awake. What you are feeling is not weakness. It is the weight of a question that deserves a serious answer.

The answer may not be what you fear. If it is, you will face it with more information and better options than any generation before you. Neither of those facts makes this easy. Both of them are true.